(2R,5S)-1-allyl-2,5-dimethylpiperazine -Drug Synthesis Database

【结构式】

【分子编号】20690

【品名】(2R,5S)-1-allyl-2,5-dimethylpiperazine

【CA登记号】

【分子式】C₉H₁₈N₂

【分子量】154.2554

【元素组成】C 70.08% H 11.76% N 18.16%

与该中间体有关的原料药合成路线共 10 条

合成路线1 合成路线2 合成路线3 合成路线4 合成路线5 合成路线6 合成路线7 合成路线8 合成路线9 合成路线10

合成路线1

该中间体在本合成路线中的序号：(IX)

The alkylation of trans-2,5-dimethylpiperazine (VIII) with allyl bromide gave rise to a racemic mixture of N-allylpiperazines, which was resolved using (-)-camphoric acid. The desired (2R,5S)-piperazine (IX) was then alkylated with benzhydryl chloride (VII) producing a mixture of the title compound and its benzhydryl epimer (X), which were separated by flash column chromatography.

参考文献中间体

合成目标

【1】 Evans, S.M.; Lenz, G.R.; Probes of receptor mediated phenomena 19. Synthesis of (+)-4-[(alphaR)-alpha((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80): A highly selective, nonpeptide delta opioid receptor agonist. Chemtracts - Org Chem 1994, 7, 6, 395.
【2】 Calderon, S.N.; et al.; Probes for narcotic receptor mediated phenomena: 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2, 5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N, N-diethylbenzamide (SNC 80). J Med Chem 1997, 40, 5, 695.
【3】 Calderon, S.N.; et al.; Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2, 5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N, N-diethylbenzamide (SNC 80): A highly selective, nonpeptide delta opioid receptor agonist. J Med Chem 1994, 14, 37, 2125.

中间体序号	中间体编号	品名	分子式	供应商	用于合成
(VII)	56249	4-[chloro(3-methoxyphenyl)methyl]-N,N-diethylbenzamide	C₁₉H₂₂ClNO₂	详情	详情
(VIII)	20687	(2R,5S)-2,5-dimethylpiperazine	C₆H₁₄N₂	详情	详情
(IX)	20690	(2R,5S)-1-allyl-2,5-dimethylpiperazine	C₉H₁₈N₂	详情	详情
(X)	56250	4-[(S)-[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](3-methoxyphenyl)methyl]-N,N-diethylbenzamide	C₂₈H₃₉N₃O₂	详情	详情

合成路线2

该中间体在本合成路线中的序号：(IX)

In a different synthetic strategy, 4-formylbenzoic acid (XI) was first coupled to diethylamine by means of EDC to yield N,N-diethyl 4-formylbenzamide (XII). The intermediate iminium salt produced by condensation between aldehyde (XII) and the chiral piperazine (IX) was then isolated as the benzotriazole adduct (XIII). Displacement of the benzotriazolyl group by the Grignard reagent (XIV) produced the title diastereoisomer as the major product, which was further enriched by recrystallization from acetonitrile/water.

参考文献中间体

合成目标

【1】 Report from ASCO 2002 - Docetaxel improves survival in node-positive early-stage breast cancer patients. Oncology (USA) 2002, 16, 8, 1054.

中间体序号	中间体编号	品名	CAS号	分子式	供应商	用于合成
(IX)	20690	(2R,5S)-1-allyl-2,5-dimethylpiperazine		C₉H₁₈N₂	详情	详情
(XI)	18922	4-formylbenzoic acid	619-66-9	C₈H₆O₃	详情	详情
(XII)	45932	N,N-diethyl-4-formylbenzamide		C₁₂H₁₅NO₂	详情	详情
(XIII)	56251	4-[[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](1H-1,2,3-benzotriazol-1-yl)methyl]-N,N-diethylbenzamide		C₂₇H₃₆N₆O	详情	详情
(XIV)	35984	bromo(3-methoxyphenyl)magnesium	36282-40-3	C₇H₇BrMgO	详情	详情

合成路线3

该中间体在本合成路线中的序号：(IV)

Treatment of trans-2,5-dimethylpiperazine (I) with ethyl chloroformate gave racemic ethyl carbamate (II), which was subsequently alkylated with allyl bromide, and then deprotected with ethanolic KOH to yield racemic piperazine (IV). Separation of the desired enantiomer (V) was achieved through recrystallization of the salt with di-p-toluoyl-D-tartaric acid, followed by liberation of the base with NaOH.

参考文献中间体

合成目标

【1】 Chang, K.-J.; Bishop, M.J.; Bubacz, D.G.; McNutt, R.W. Jr. (Glaxo Wellcome plc); Piperazine cpds. used in therapy. EP 0711289; JP 1997501156; WO 9504051 .
【2】 Chang, K.; Boswell, G.E.; Bubacz, D.G.; Collins, M.A.; Davis, A.O.; McNutt, R.W. (Delta Pharmaceuticals, Inc.); Opioid diarylmethylpiperazines and piperidines. JP 1995503247; US 5658908; US 5681830; WO 9315062 .

中间体序号	中间体编号	品名	分子式	供应商	用于合成
(I)	20687	(2R,5S)-2,5-dimethylpiperazine	C₆H₁₄N₂	详情	详情
(II)	20688	ethyl (2S,5R)-2,5-dimethyl-1-piperazinecarboxylate	C₉H₁₈N₂O₂	详情	详情
(III)	20689	ethyl (2S,5R)-4-allyl-2,5-dimethyl-1-piperazinecarboxylate	C₁₂H₂₂N₂O₂	详情	详情
(IV)	20690	(2R,5S)-1-allyl-2,5-dimethylpiperazine	C₉H₁₈N₂	详情	详情
(V)	20690	(2R,5S)-1-allyl-2,5-dimethylpiperazine	C₉H₁₈N₂	详情	详情

合成路线4

该中间体在本合成路线中的序号：(V)

参考文献中间体

合成目标

【1】 Chang, K.-J.; Bishop, M.J.; Bubacz, D.G.; McNutt, R.W. Jr. (Glaxo Wellcome plc); Piperazine cpds. used in therapy. EP 0711289; JP 1997501156; WO 9504051 .
【2】 Chang, K.; Boswell, G.E.; Bubacz, D.G.; Collins, M.A.; Davis, A.O.; McNutt, R.W. (Delta Pharmaceuticals, Inc.); Opioid diarylmethylpiperazines and piperidines. JP 1995503247; US 5658908; US 5681830; WO 9315062 .

中间体序号	中间体编号	品名	分子式	供应商	用于合成
(I)	20687	(2R,5S)-2,5-dimethylpiperazine	C₆H₁₄N₂	详情	详情
(II)	20688	ethyl (2S,5R)-2,5-dimethyl-1-piperazinecarboxylate	C₉H₁₈N₂O₂	详情	详情
(III)	20689	ethyl (2S,5R)-4-allyl-2,5-dimethyl-1-piperazinecarboxylate	C₁₂H₂₂N₂O₂	详情	详情
(IV)	20690	(2R,5S)-1-allyl-2,5-dimethylpiperazine	C₉H₁₈N₂	详情	详情
(V)	20690	(2R,5S)-1-allyl-2,5-dimethylpiperazine	C₉H₁₈N₂	详情	详情

合成路线5

该中间体在本合成路线中的序号：(V)

Alternatively, a chiral synthesis of intermediate (V) was developed from enantiopure amino acids. N-Boc-D-alanine (VI) was N-alkylated with allyl bromide in the presence of two equivalents of NaH, and the resulting N-allyl amino acid (VII) was coupled with L-alanine methyl ester (VIII) using 1-dimethylaminopropyl-3-ethylcarbodiimide (DEC) to provide dipeptide (IX). Subsequent acid treatment of (IX) produced both Boc deprotection and cyclization to the diketopiperazine (X), which was finally reduced to piperazine (V) with LiAlH4.

参考文献中间体

合成目标

【1】 Chang, K.-J.; Bishop, M.J.; Bubacz, D.G.; McNutt, R.W. Jr. (Glaxo Wellcome plc); Piperazine cpds. used in therapy. EP 0711289; JP 1997501156; WO 9504051 .
【2】 Chang, K.; Boswell, G.E.; Bubacz, D.G.; Collins, M.A.; Davis, A.O.; McNutt, R.W. (Delta Pharmaceuticals, Inc.); Opioid diarylmethylpiperazines and piperidines. JP 1995503247; US 5658908; US 5681830; WO 9315062 .

中间体序号	中间体编号	品名	CAS号	分子式	供应商	用于合成
(V)	20690	(2R,5S)-1-allyl-2,5-dimethylpiperazine		C₉H₁₈N₂	详情	详情
(VI)	15859	Boc-D-Alanine; (2R)-2-[(tert-butoxycarbonyl)amino]propionic acid	7764-95-6	C₈H₁₅NO₄	详情	详情
(VII)	20693	(2R)-2-[allyl(tert-butoxycarbonyl)amino]propionic acid		C₁₁H₁₉NO₄	详情	详情
(VIII)	20694	methyl (2S)-2-aminopropanoate		C₄H₉NO₂	详情	详情
(IX)	20695	(2S)-2-([(2R)-2-[allyl(tert-butoxycarbonyl)amino]propanoyl]amino)propionic acid		C₁₄H₂₄N₂O₅	详情	详情
(X)	20696	(3S,6R)-1-allyl-3,6-dimethyl-2,5-piperazinedione		C₉H₁₄N₂O₂	详情	详情

合成路线6

该中间体在本合成路线中的序号：(V)

The title compound was synthesized by two related procedures. 3-Fluoro-N-methylaniline (XIV) was obtained from 3-fluoroaniline (XI) by condensation with 1-(hydroxymethyl)benzotriazole (XII), followed by reduction of the anilinomethylbenzotriazole (XIII) with NaBH4. Subsequent condensation with 3-formylbenzoyl chloride (XV) (prepared from the corresponding acid and SOCl2) provided amide (XVI). Then, condensation of (XVI) with piperazine (V) and benzotriazole in the presence of a catalytic amount of Et3N in refluxing toluene furnished (XVII) as a mixture of epimers. 3-Bromophenol (XVIII) was protected as the silyl ether (XIX) with tert-butyldimethylsilyl chloride and imidazole. This compound was converted to the organolithium derivative with n-butyllithium in THF at -78 C, and further transformed to the arylmagnesium reagent (XX) by treatment with magnesium bromide etherate in THF. Condensation of (XVII) with organometallic compound (XX) afforded the benzhydrylpiperazine (XXI) as a 10:1 mixture of epimers. Desilylation of (XXI) by treatment with HCl in aqueous THF, followed by recrystallization of the major isomer from EtOAc/hexane yielded the title compound.

参考文献中间体

合成目标

【1】 Chang, K.; Boswell, G.E.; Bubacz, D.G.; Collins, M.A.; Davis, A.O.; McNutt, R.W. (Delta Pharmaceuticals, Inc.); Opioid diarylmethylpiperazines and piperidines. JP 1995503247; US 5658908; US 5681830; WO 9315062 .
【2】 Chang, K.-J.; Bishop, M.J.; Bubacz, D.G.; McNutt, R.W. Jr. (Glaxo Wellcome plc); Piperazine cpds. used in therapy. EP 0711289; JP 1997501156; WO 9504051 .

中间体序号	中间体编号	品名	CAS号	分子式	供应商	用于合成
(V)	20690	(2R,5S)-1-allyl-2,5-dimethylpiperazine		C₉H₁₈N₂	详情	详情
(XI)	20697	3-fluoroaniline; 3-fluorophenylamine	372-19-0	C₆H₆FN	详情	详情
(XII)	20698	1H-1,2,3-benzotriazol-1-ylmethanol	28539-02-8	C₇H₇N₃O	详情	详情
(XIII)	20699	N-(1H-1,2,3-benzotriazol-1-ylmethyl)-3-fluoroaniline; N-(1H-1,2,3-benzotriazol-1-ylmethyl)-N-(3-fluorophenyl)amine		C₁₃H₁₁FN₄	详情	详情
(XIV)	20700	3-fluoro-N-methylaniline; N-(3-fluorophenyl)-N-methylamine		C₇H₈FN	详情	详情
(XV)	20701	3-formylbenzoyl chloride		C₈H₅ClO₂	详情	详情
(XVI)	20702	N-(3-fluorophenyl)-3-formyl-N-methylbenzamide		C₁₅H₁₂FNO₂	详情	详情
(XVII)	20703	3-[[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](1H-1,2,3-benzotriazol-1-yl)methyl]-N-(3-fluorophenyl)-N-methylbenzamide		C₃₀H₃₃FN₆O	详情	详情
(XVIII)	20704	3-bromophenol	591-20-8	C₆H₅BrO	详情	详情
(XIX)	20705	(3-bromophenoxy)(tert-butyl)dimethylsilane; 3-bromophenyl tert-butyl(dimethyl)silyl ether	65423-56-5	C₁₂H₁₉BrOSi	详情	详情
(XX)	20706	bromo(3-[[tert-butyl(dimethyl)silyl]oxy]phenyl)magnesium		C₁₂H₁₉BrMgOSi	详情	详情
(XXI)	20707	3-[[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](3-[[tert-butyl(dimethyl)silyl]oxy]phenyl)methyl]-N-(3-fluorophenyl)-N-methylbenzamide		C₃₆H₄₈FN₃O₂Si	详情	详情

合成路线7

该中间体在本合成路线中的序号：(V)

In an alternative procedure, the silylether of 3-bromophenol (XIX) was converted to the organolithium compound (XXII) and then coupled to 3-bromobenzaldehyde (XXIII) in THF at -78 C. The resulting benzhydrol (XXIV) was treated with SOCl2 to give chloride (XXV), which was subsequently condensed with piperazine (V) in refluxing acetonitrile. The diastereomeric mixture of benzhydryl piperazines (XXVI) was desilylated with tetraethylammonium fluoride, and the major isomer (XXVII) was isolated by recrystallization from acetonitrile. The bromo substituent of (XXVII) was then substituted for a cyano group upon treatment with CuCN in N-methylpyrrolidinone at 170 C. Basic hydrolysis of nitrile (XXVIII) gave acid (XXIX), which was protected as the tert-butyldimethylsilyl ether and further converted to acid chloride (XXX) by reaction with oxalyl chloride and a catalytic amount of DMF. Finally, acid chloride (XXX) was condensed with N-methyl-3-fluoroaniline (XIV), and the silyl protecting group was removed by treatment with tetraethylammonium fluoride in acetonitrile.

参考文献中间体

合成目标

【1】 Chang, K.-J.; Bishop, M.J.; Bubacz, D.G.; McNutt, R.W. Jr. (Glaxo Wellcome plc); Piperazine cpds. used in therapy. EP 0711289; JP 1997501156; WO 9504051 .
【2】 Chang, K.; Boswell, G.E.; Bubacz, D.G.; Collins, M.A.; Davis, A.O.; McNutt, R.W. (Delta Pharmaceuticals, Inc.); Opioid diarylmethylpiperazines and piperidines. JP 1995503247; US 5658908; US 5681830; WO 9315062 .

中间体序号	中间体编号	品名	CAS号	分子式	供应商	用于合成
(V)	20690	(2R,5S)-1-allyl-2,5-dimethylpiperazine		C₉H₁₈N₂	详情	详情
(XIV)	20700	3-fluoro-N-methylaniline; N-(3-fluorophenyl)-N-methylamine		C₇H₈FN	详情	详情
(XIX)	20705	(3-bromophenoxy)(tert-butyl)dimethylsilane; 3-bromophenyl tert-butyl(dimethyl)silyl ether	65423-56-5	C₁₂H₁₉BrOSi	详情	详情
(XXII)	20708	(3-[[tert-butyl(dimethyl)silyl]oxy]phenyl)lithium		C₁₂H₁₉LiOSi	详情	详情
(XXIII)	10477	3-Bromobenzaldehyde; m-Bromobenzaldehyde	3132-99-8	C₇H₅BrO	详情	详情
(XXIV)	20710	(3-bromophenyl)(3-[[tert-butyl(dimethyl)silyl]oxy]phenyl)methanol		C₁₉H₂₅BrO₂Si	详情	详情
(XXV)	20711	3-[(3-bromophenyl)(chloro)methyl]phenyl tert-butyl(dimethyl)silyl ether; [3-[(3-bromophenyl)(chloro)methyl]phenoxy](tert-butyl)dimethylsilane		C₁₉H₂₄BrClOSi	详情	详情
(XXVI)	20712	(2R,5S)-1-allyl-4-[(3-bromophenyl)(3-[[tert-butyl(dimethyl)silyl]oxy]phenyl)methyl]-2,5-dimethylpiperazine; 3-[[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](3-bromophenyl)methyl]phenyl tert-butyl(dimethyl)silyl ether		C₂₈H₄₁BrN₂OSi	详情	详情
(XXVII)	20713	3-[(S)-[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](3-bromophenyl)methyl]phenol		C₂₂H₂₇BrN₂O	详情	详情
(XXVIII)	20714	3-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](3-hydroxyphenyl)methyl]benzonitrile		C₂₃H₂₇N₃O	详情	详情
(XXIX)	20715	3-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](3-hydroxyphenyl)methyl]benzoic acid		C₂₃H₂₈N₂O₃	详情	详情
(XXX)	20716	3-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](3-[[tert-butyl(dimethyl)silyl]oxy]phenyl)methyl]benzoyl chloride		C₂₉H₄₁ClN₂O₂Si	详情	详情

合成路线8

该中间体在本合成路线中的序号：(III)

The alkylation of the prochiral trans-2,5-dimethylpiperazine (I) with allyl bromide (II) produced a racemic mixture of N-allyl piperazines. After separation of the (+)-isomer by precipitation with (+)-camphoric acid, the desired (-)-piperazine (III) was isolated from the remaining enriched mixture by crystallization as the di-p-toluoyl-D-tartrate salt.

参考文献中间体

合成目标

【1】 Maw, G.N. (Pfizer Inc.); Anti-inflammatory piperazinyl-benzyl-tetrazole derivs. and intermediates thereof. EP 0983251; JP 2000513024; WO 9852929 .

中间体序号	中间体编号	品名	CAS号	分子式	供应商	用于合成
(I)	20687	(2R,5S)-2,5-dimethylpiperazine		C₆H₁₄N₂	详情	详情
(II)	11463	3-Bromo-1-propene; 3-Bromopropene；allyl bromide	106-95-6	C₃H₅Br	详情	详情
(III)	20690	(2R,5S)-1-allyl-2,5-dimethylpiperazine		C₉H₁₈N₂	详情	详情

合成路线9

该中间体在本合成路线中的序号：(III)

The condensation between aldehyde (VII), piperazine (III) and benzotriazole furnished adduct (VIII). The Grignard reagent (X), prepared by silylation of 3-bromophenol (IX) followed by reaction with Mg, was then condensed with the benzotriazolyl adduct (VIII) to give the (diarylmethyl)piperazine (XI). Finally, basic hydrolysis of the ethyl ester of (XI) yielded the title compound.

参考文献中间体

合成目标

【1】 Maw, G.N. (Pfizer Inc.); Anti-inflammatory piperazinyl-benzyl-tetrazole derivs. and intermediates thereof. EP 0983251; JP 2000513024; WO 9852929 .

中间体序号	中间体编号	品名	CAS号	分子式	供应商	用于合成
(III)	20690	(2R,5S)-1-allyl-2,5-dimethylpiperazine		C₉H₁₈N₂	详情	详情
(VII)	48160	ethyl 5-[5-(4-formylphenyl)-2H-1,2,3,4-tetraazol-2-yl]pentanoate		C₁₅H₁₈N₄O₃	详情	详情
(VIII)	48161	ethyl 5-(5-[4-[[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](1H-1,2,3-benzotriazol-1-yl)methyl]phenyl]-2H-1,2,3,4-tetraazol-2-yl)pentanoate		C₃₀H₃₉N₉O₂	详情	详情
(IX)	20704	3-bromophenol	591-20-8	C₆H₅BrO	详情	详情
(X)	48162	bromo[3-[(trimethylsilyl)oxy]phenyl]magnesium		C₉H₁₃BrMgOSi	详情	详情
(XI)	48163	ethyl 5-(5-[4-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](3-hydroxyphenyl)methyl]phenyl]-2H-1,2,3,4-tetraazol-2-yl)pentanoate		C₃₀H₄₀N₆O₃	详情	详情

合成路线10

该中间体在本合成路线中的序号：(III)

A related procedure for the synthesis of the precursor ethyl ester (XI) was also reported. The condensation between 4-formylbenzonitrile (IV), piperazine (III) and benzotriazole furnished the benzotriazolyl adduct (XII). Subsequent reaction of (XII) with the Grignard reagent (XIII) yielded the (diarylmethyl)piperazine (XIV). The cyano group of (XIV) was then converted to the tetrazole (XV) by treatment with trimethylsilyl azide and dibutyltin oxide. Alkylation of tetrazole (XV) with ethyl 5-bromovalerate (VI) gave rise to a mixture of 1-triazolyl (XVII) and 2-triazolylpentanoate (XVI). After desilylation of this mixture with tetraethylammonium fluoride, the desired 2-triazolyl derivative (XI) was isolated by column chromatography.

参考文献中间体

合成目标

【1】 Maw, G.N. (Pfizer Inc.); Anti-inflammatory piperazinyl-benzyl-tetrazole derivs. and intermediates thereof. EP 0983251; JP 2000513024; WO 9852929 .

中间体序号	中间体编号	品名	CAS号	分子式	供应商	用于合成
(III)	20690	(2R,5S)-1-allyl-2,5-dimethylpiperazine		C₉H₁₈N₂	详情	详情
(IV)	17552	4-formylbenzonitrile; 4-Cyanobenzaldehyde	105-07-7	C₈H₅NO	详情	详情
(VI)	37151	ethyl 5-bromopentanoate	14660-52-7	C₇H₁₃BrO₂	详情	详情
(XI)	48163	ethyl 5-(5-[4-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](3-hydroxyphenyl)methyl]phenyl]-2H-1,2,3,4-tetraazol-2-yl)pentanoate		C₃₀H₄₀N₆O₃	详情	详情
(XII)	48164	4-[[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](1H-1,2,3-benzotriazol-1-yl)methyl]benzonitrile		C₂₃H₂₆N₆	详情	详情
(XIII)	20706	bromo(3-[[tert-butyl(dimethyl)silyl]oxy]phenyl)magnesium		C₁₂H₁₉BrMgOSi	详情	详情
(XIV)	48165	4-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](3-[[tert-butyl(dimethyl)silyl]oxy]phenyl)methyl]benzonitrile		C₂₉H₄₁N₃OSi	详情	详情
(XV)	48166	(2R,5S)-1-allyl-4-[(R)-(3-[[tert-butyl(dimethyl)silyl]oxy]phenyl)[4-(1H-1,2,3,4-tetraazol-5-yl)phenyl]methyl]-2,5-dimethylpiperazine; 3-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl][4-(1H-1,2,3,4-tetraazol-5-yl)phenyl]methyl]phenyl tert-butyl(dimethyl)silyl ether		C₂₉H₄₂N₆OSi	详情	详情
(XVI)	48168	ethyl 5-(5-[4-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](3-[[tert-butyl(dimethyl)silyl]oxy]phenyl)methyl]phenyl]-1H-1,2,3,4-tetraazol-1-yl)pentanoate		C₃₆H₅₄N₆O₃Si	详情	详情
(XVII)	48167	ethyl 5-(5-[4-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazinyl](3-[[tert-butyl(dimethyl)silyl]oxy]phenyl)methyl]phenyl]-2H-1,2,3,4-tetraazol-2-yl)pentanoate		C₃₆H₅₄N₆O₃Si	详情	详情

Extended Information